20448-79-7
20448-79-7 結(jié)構(gòu)式
基本信息
2-氨基-2-去甲菠烷羧酸
2-氨基二環(huán)[2.2.1]庚烷-2-羧酸
2-氨基雙環(huán)[2.2.1]庚烷-2-羧酸
物理化學(xué)性質(zhì)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2024/11/08 | HY-108540 | 2-氨基-2-去甲菠烷羧酸 LAT1-IN-1 | 20448-79-7 | 50mg | 600元 |
| 2024/11/08 | HY-108540 | 2-氨基-2-去甲菠烷羧酸 LAT1-IN-1 | 20448-79-7 | 10mM * 1mLin Water | 660元 |
| 2024/11/08 | HY-108540 | 2-氨基-2-去甲菠烷羧酸 LAT1-IN-1 | 20448-79-7 | 100mg | 1000元 |
常見問題列表
| Target | Value |
|
LAT1
() |
LAT1-IN-1 (1-100 mM; 3 days; KYSE30 and KYSE150 esophageal cancer cells) treatment suppresses cell proliferation in a dose-dependent manner.
LAT1-IN-1 (30 mM; 24 and 48 hours; KYSE30 and KYSE150 cells) treatment significantly increases cell population in the G0/G1 phase in both KYSE30 and KYSE150 cells, indicating that LAT1-IN-1 induces cell cycle arrest at G1 phase.
LAT1-IN-1 (30 mM; 0-24 hours; KYSE30 and KYSE150 cells) treatment decreases phosphorylation of 4E-BP1 and p70S6K at 30 minutes and the decrease is continued for 24 hours. The amount of mTOR, 4E-BP1, and p70S6K proteins is slightly decreased.
Cell Proliferation Assay
| Cell Line: | KYSE30 and KYSE150 esophageal cancer cells |
| Concentration: | 1 mM, 3 mM, 5 mM, 10 mM, 20 mM, 30 mM, 40 mM, 50 mM, or 100 mM |
| Incubation Time: | 3 days |
| Result: | Cell proliferation was suppressed in a dose-dependent manner. |
Cell Cycle Analysis
| Cell Line: | KYSE30 and KYSE150 cells |
| Concentration: | 30 mM |
| Incubation Time: | 24 and 48 hours |
| Result: | Cell cycle arrest. |
Western Blot Analysis
| Cell Line: | KYSE30 and KYSE150 cells |
| Concentration: | 30 mM |
| Incubation Time: | 0 hour, 0.5 hour, 1 hour, 3 hours, 6 hours, 24 hours |
| Result: | Phosphorylation of 4E-BP1 and p70S6K was decreased. The amount of mTOR, 4E-BP1, and p70S6K proteins was slightly decreased. |
LAT1-IN-1 (200 mg/kg; intravenous injection; daily; for 14 days; male BALB/c nude mice) treatment significantly delays tumor growth and decreases glucose metabolism, indicating that LAT1 inhibition potentially suppresses esophageal cancer growth in vivo.
| Animal Model: | Male BALB/c nude mice (5-week-old) with KYSE150 cells |
| Dosage: | 200 mg/kg |
| Administration: | Intravenous injection; daily; for 14 days |
| Result: | Significantly delayed tumor growth and decreased glucose metabolism. |